File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma

TitleRecombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma
Authors
Issue Date2002
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.com
Citation
Journal Of Clinical Gastroenterology, 2002, v. 35 n. 3, p. 272-275 How to Cite?
AbstractAt present, there is no effective treatment of metastatic hepatocellular carcinoma (HCC). Systemic interferon alfa (IFN-α) was found to be of some use in patients with inoperable HCC in two randomized trials. We report a case in which metastatic HCC was cured by systemic IFN-α 2b in combination with surgery. A patient developed two bilateral pulmonary metastatic HCC nodules 5 months after the resection of the primary HCC. He was treated with systemic IFN-α 2b. One lesion completely disappeared. The other lesion showed an initial response but became resistant to the IFN-α 2b therapy after reduction in dosage because of the side effects. This was resected in view of the absence of new metastases after 9 months of IFN-α 2b therapy. He remained free from recurrence at 59 months of follow-up. A rare, but reversible, complication of retinal cotton wool spots caused by IFN-α 2b occurred in this patient, IFN-α 2b is partially effective in treating metastatic HCC. The time for its administration can also serve as an observation period, which is vital in deciding whether definitive surgical treatment of any residual lesions is indicated.
Persistent Identifierhttp://hdl.handle.net/10722/162629
ISSN
2015 Impact Factor: 3.163
2015 SCImago Journal Rankings: 1.274
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_US
dc.contributor.authorHon, Cen_US
dc.contributor.authorHui, CKen_US
dc.contributor.authorSiu, CWen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:21:50Z-
dc.date.available2012-09-05T05:21:50Z-
dc.date.issued2002en_US
dc.identifier.citationJournal Of Clinical Gastroenterology, 2002, v. 35 n. 3, p. 272-275en_US
dc.identifier.issn0192-0790en_US
dc.identifier.urihttp://hdl.handle.net/10722/162629-
dc.description.abstractAt present, there is no effective treatment of metastatic hepatocellular carcinoma (HCC). Systemic interferon alfa (IFN-α) was found to be of some use in patients with inoperable HCC in two randomized trials. We report a case in which metastatic HCC was cured by systemic IFN-α 2b in combination with surgery. A patient developed two bilateral pulmonary metastatic HCC nodules 5 months after the resection of the primary HCC. He was treated with systemic IFN-α 2b. One lesion completely disappeared. The other lesion showed an initial response but became resistant to the IFN-α 2b therapy after reduction in dosage because of the side effects. This was resected in view of the absence of new metastases after 9 months of IFN-α 2b therapy. He remained free from recurrence at 59 months of follow-up. A rare, but reversible, complication of retinal cotton wool spots caused by IFN-α 2b occurred in this patient, IFN-α 2b is partially effective in treating metastatic HCC. The time for its administration can also serve as an observation period, which is vital in deciding whether definitive surgical treatment of any residual lesions is indicated.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.comen_US
dc.relation.ispartofJournal of Clinical Gastroenterologyen_US
dc.rightsJournal of Clinical Gastroenterology. Copyright © Lippincott Williams & Wilkins.-
dc.subject.meshAntineoplastic Agents - Therapeutic Useen_US
dc.subject.meshCarcinoma, Hepatocellular - Drug Therapy - Secondary - Surgeryen_US
dc.subject.meshHepatectomyen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-Alpha - Therapeutic Useen_US
dc.subject.meshIschemia - Chemically Induceden_US
dc.subject.meshLiver Neoplasms - Drug Therapy - Pathology - Surgeryen_US
dc.subject.meshLung Neoplasms - Drug Therapy - Secondary - Surgeryen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPneumonectomyen_US
dc.subject.meshRecombinant Proteinsen_US
dc.subject.meshRetinaen_US
dc.subject.meshRetinal Vessels - Drug Effectsen_US
dc.subject.meshAlpha-Fetoproteins - Analysisen_US
dc.titleRecombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.emailSiu, CW:cwdsiu@hkucc.hku.hken_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.identifier.authoritySiu, CW=rp00534en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/00004836-200209000-00015en_US
dc.identifier.pmid12192207-
dc.identifier.scopuseid_2-s2.0-0036720611en_US
dc.identifier.hkuros80565-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036720611&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume35en_US
dc.identifier.issue3en_US
dc.identifier.spage272en_US
dc.identifier.epage275en_US
dc.identifier.isiWOS:000177611900015-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.scopusauthoridHon, C=7003617146en_US
dc.identifier.scopusauthoridHui, CK=7202876933en_US
dc.identifier.scopusauthoridSiu, CW=7006550690en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats